Herramientas para erradicar la polio

1. Sutter RW, Kew OM, Cochi SL, Aylward B. Poliovirus vaccine—live. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Edinburgh, United Kingdom: Elsevier/Saunders; 2013:598–645
2. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010;172(11):1213–1229
3. Vidor E, Plotkin SA. Poliovirus vaccine— inactivated. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Edinburgh, United Kingdom: Elsevier/Saunders; 2013:573–597
4. Grassly NC. The final stages of the global eradication of poliomyelitis. Philos Trans R Soc Lond B Biol Sci. 2013;368(1623):1–14
5. Grassly NC, Jafari H, Bahl S, et al. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis. 2009;200(5):794–801
6. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13(5):926–939
7. Global Polio Eradication Initiative. Polio this week: as of October 28, 2014. Available at: www.polioeradication.org/ Dataandmonitoring/Poliothisweek.aspx. Accessed October 28, 2014
8. Mundel T, Orenstein WA. No country is safe without global eradication of poliomyelitis. N Engl J Med. 2013;369(21): 2045–2046
9. Global Polio Eradication Initiative. Supplementary immunization. Available at: www.polioeradication.org/Aboutus/ Strategy/Supplementaryimmunization. aspx. Accessed April 7, 2014
10. Obregón R, Chitnis K, Morry C, et al. Achieving polio eradication: a review of health communication evidence and lessons learned in India and Pakistan. Bull World Health Organ. 2009;87(8):624–630
11. Aylward B, Tangermann R. The global polio eradication initiative: lessons learned and prospects for success. Vaccine. 2011;29(suppl 4):D80–D85
12. Aylward B, Yamada T. The polio endgame. N Engl J Med. 2011;364(24):2273–2275
13. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992;14(2):568–579
14. Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010;376(9753):1682–1688
15. Deshpande JM, Nadkarni SS, Siddiqui ZA. Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. Indian J Med Res. 2003;118:217–223
16. World Health Organization. IPV recommended for countries to mitigate risks and consequences associated with OPV2 withdrawal. SAGE November 2012 meeting documentation. Geneva, Switzerland: World Health Organization; November 2012. Available at: www.who. int/immunization/sage/meetings/2012/ november/news_sage_ipv_opv_nov2012/en/. Accessed April 7, 2014
17. Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation
of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis. 1990;162(6):1291–1297
18. Estívariz CF, Jafari H, Sutter RW, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a communitybased, randomised controlled trial. Lancet Infect Dis. 2012;12(2):128–135
19. Moriniere BJ, van Loon FP, Rhodes PH, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet. 1993;341(8860):1545–1550
20. Global Polio Eradication Initiative. Polio Eradication & Endgame Strategic Plan 2013-2018. Geneva, Switzerland: World Health Organization; 2013. Available at: www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_US.pdf. Accessed April 7, 2014
21. World Health Organization. 7th Meeting of the SAGE Polio Working Group: note for the record. Geneva, Switzerland: World Health Organization; 2013. Available at: www.who.int/immunization/sage/meetings/2013/november/3_SAGE_ Note_for_the_Record_exec_summary. pdf. Accessed April 7, 2014
22. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Expert review on
poliovirus immunity and transmission. Risk Anal. 2013;33(4):544–605
23. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Economic analysis of the global polio eradication initiative. Vaccine. 2010; 29(2):334–343
24. Bhutta ZA, Orenstein WA; Scientific Experts Against Polio. Scientific declaration on polio eradication. Vaccine. 2013;31(27):2850–2851
25. Thompson KM, Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet. 2007; 369(9570):1363–1371
26. Scientific Experts Against Polio. Scientific declaration on polio eradication. Available at: http://vaccines.emory.edu/poliodeclaration/ text.pdf. Accessed April 7, 2014
27. Centers for Disease Control and Prevention. Polio: for Travelers. Available at: http://www. cdc.gov/polio/us/travelers.html. Accessed November 3, 2014